First Name: Lindsay Last Name: Morton

Institution: National Cancer Institute

Address 1: 6120 Executive Blvd EPS 7040

Address 2: City: Rockville State/Province: MD

Country: Zip: 20852

Phone: 3014353972 Alternate Phone:

Email: mortonli@mail.nih.gov

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes

The specific aims are clear and focused.: Yes

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

Project Title: Comparison of radiation dose reconstruction methods for subsequent neoplasm studies

Planned research population (eligibility criteria): All CCSS participants (diagnosed 1970-1986) will be included. Analyses will focus on participants who agreed to the release of their medical records to obtain information on radiotherapy, with a particular emphasis on participants who were included in the previous case-control studies of radiation dose and risk of subsequent central nervous system, breast, sarcoma, and skin neoplasms.

Proposed specific aims: Assess the validity of the "region-based" SN dose reconstruction by comparing the categorized maximum treatment dose to body regions including the SN to that obtained from the detailed dosimetry conducted for patients from previous case-control studies. The results of this analysis will provide a foundation for CCSS projects that use the region-based dose estimates.

Will the project require non-CCSS funding to complete?: Yes

If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: The funding for the dosimetry, analysis, and manuscript preparation comes from the Intramural Program, National Cancer Institute.

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: No

Biological Samples: No

Medical record data: No If yes to any of the above, please briefly describe.:
What CCSS Working Group(s) would likely be involved? (Check all that apply)
Second Malignancy: Primary Chronic Disease: Psychology / Neuropsychology: Genetics: Secondary Cancer Control: Epidemiology / Biostatistics: Secondary
To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as <u>outcome</u> (primary or secondary) or <u>correlative factors</u> . (Check all that apply)
Late mortality: Second Malignancy: Primary
Health Behaviors
Tobacco: Alcohol: Physical activity: Medical screening: Other: If other, please specify:
Psychosocial
Insurance: Marriage: Education: Employment: Other: If other, please specify:
Medical conditions
Hearing/Vision/Speech: Hormonal systems: Heart and vascular: Respiratory: Digestive: Surgical procedures: Brain and nervous system:

Other:
If other, please specify:
Medications
Describe medications:
Pregnancy and offspring: Family History:
Psychologic/Quality of Life
BSI-18: SF-36: CCSS-NCQ: PTS: PTG: Other: If other, please specify:
Chronic conditions (CTCAE v3): Health status:
Demographic
Age: Correlative Factors Race: Sex: Correlative Factors Others: If others, please specify:
Cancer treatment
Chemotherapy: Radiation therapy: Correlative Factors Surgery:
Anticipated sources of statistical support
CCSS Statistical Center:

Local institutional statistician: Yes If local, please provide the name(s) and contact information of the statistician(s) to be involved.:

If yes, which of the following?	
Buccal cell DNA:	
Peripheral blood:	
Lymphoblastoid cell lines:	
Second malignancy pathology samples:	
Other requiring collection of samples:	
If other, please explain:	